<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Available basal insulin formulations do not provide a constant and reliable 24-h insulin supply </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the efficacy and safety of glargine (a long-acting insulin analog) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulins in insulin-naive type 2 diabetic patients treated with oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: There were 426 type 2 diabetic patients (age 59 +/- 9 years, BMI 28.9 +/- 4.3 kg/m2, mean +/- SD) with poor glycemic control on oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents randomized to treatment for 1 year with bedtime insulin glargine or bedtime <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> insulin </plain></SENT>
<SENT sid="3" pm="."><plain>Oral agents were continued unchanged </plain></SENT>
<SENT sid="4" pm="."><plain>The fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (FBG) target was 6.7 mmol/l (120 mg/dl) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Average glycemic control improved similarly with both insulins (HbA(1c), [reference range &lt;6.5%] 8.3 +/- 0.1 vs. 8.2 +/- 0.1% at 1 year, glargine vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>, mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>, P &lt; 0.001 vs. baseline for both) </plain></SENT>
<SENT sid="6" pm="."><plain>However, there was less nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> (9.9 vs. 24.0% of <z:hpo ids='HP_0000001'>all</z:hpo> patients, glargine vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e>, P &lt; 0.001) and lower post-dinner <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations (9.9 +/- 0.2 vs. 10.7 +/- 0.3 mmol/l, P &lt; 0.02) with insulin glargine than with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Insulin doses and <z:mp ids='MP_0005456'>weight gain</z:mp> were comparable </plain></SENT>
<SENT sid="8" pm="."><plain>In patients reaching target FBG, HbA(1c) averaged 7.7 and 7.6% in the glargine and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> groups at 1 year </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Use of insulin glargine compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> is associated with less nocturnal <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and lower post-dinner <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="10" pm="."><plain>These data are consistent with peakless and longer duration of action of insulin glargine compared with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Achievement of acceptable average <z:chebi fb="105" ids="17234">glucose</z:chebi> control requires titration of the insulin dose to an FBG target &lt; or =6.7 mmol/l </plain></SENT>
<SENT sid="12" pm="."><plain>These data support use of insulin glargine instead of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NPH</z:e> in insulin combination regimens in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>